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Introduction {#sec1}
============

*Coronaviridae* is a large family of single-stranded positive-sense enveloped RNA viruses that can infect most animal species (human as well as domestic and wild animals). They are known to have the largest viral RNA genome and are composed of four genera ([@bib4]). Generally, infection by human coronaviruses results in mild respiratory tract symptoms, and they are known to be one of the leading causes of the common cold ([@bib15]; [@bib17]). However, in the last 18 years, we have witnessed the emergence of highly pathogenic human coronaviruses, including the severe-acute-respiratory-syndrome-related coronavirus (SARS-CoV-1), the Middle-East-respiratory-syndrome-related coronavirus (MERS-CoV), and, at the end of 2019, the severe-acute-respiratory-syndrome-related coronavirus-2 (SARS-CoV-2) ([@bib12]). SARS-CoV-2 is responsible for the coronavirus-associated acute respiratory disease or coronavirus disease 19 (COVID-19) and represents a major global health threat, and coordinated efforts are urgently needed to treat the viral infection and stop the pandemic.

Although SARS-CoV-2 primarily targets cells of the lung epithelium, causing respiratory infection, there is growing evidence that the intestinal epithelium can also be infected. Multiple studies have reported gastrointestinal symptoms such as diarrhea at the onset of the disease and have detected the prolonged shedding of large amounts of coronavirus genomes in the feces even after the virus is not detectable in oropharyngeal swabs ([@bib33]; [@bib34]; [@bib35]; [@bib37]; [@bib30]). Although one study revealed the isolation of infectious virus particles from stool samples ([@bib29]), to date, it remains unclear how many people shed infectious viruses in feces. Most critically, it remains unknown whether or not there is a possibility for fecal transmission of SARS-CoV-2, but multiple health agencies worldwide have highlighted this possibility. The presence of such a large amount of coronavirus genomes in feces is hardly explainable by a swallowing virus replicating in the throat or by a loss of barrier function of the intestinal epithelium, which will allow the release of viruses or genomes from the inside of the body (circulation or *lamina propria*) to the lumen of the gut. Instead, it is likely due to an active replication in the intestinal epithelium. Recently, intestinal biopsies of SARS-CoV-2 infected patients clearly show the presence of replicating viruses in epithelial cells of the small and large intestine ([@bib34]). SARS-CoV-2 infection of the gastrointestinal tract is supported by the fact that ACE2, the virus receptor ([@bib8]), is expressed in intestinal epithelial cells ([@bib39]; [@bib13]; [@bib32]; [@bib26]), and single-cell sequencing analysis suggest that its expression is even higher on intestinal cells compared to lung cells ([@bib36]). This highlights that SARS-CoV-2 is not restricted to the lung and also infects the gastrointestinal tract. Importantly, many animal coronaviruses are well known to be enteric and are transmitted via the fecal-oral route ([@bib28]; [@bib27]). Additionally, the presence of human pathogenic coronaviruses in the gastrointestinal tract was previously reported for SARS-CoV-1 and MERS-CoV but remained seriously understudied ([@bib10]; [@bib31]; [@bib40]). Although it is now clear that human coronaviruses, particularly SARS-CoV-2, are found in feces and can infect the gastrointestinal tract, the importance of its enteric phase for viremia, pathogenesis, and patient prognosis remains unknown.

To combat the current pandemic of COVID-19 and prepare for potential future emerging zoonotic coronaviruses, we need to gain a better understanding of the molecular basis of SARS-CoV-2 infection, replication, and *de novo* infectious virus production in a tissue-specific manner. Here, we engaged in studying SARS-CoV-2 infection of human intestinal cells. For this, we exploited both human intestinal epithelial cell (hIEC) lines and human organoid culture models to characterize how these cells support SARS-CoV-2 replication and *de novo* infectious virus production and how they respond to viral infection. Direct comparison of both primary and transformed cells shows that hIECs fully support SARS-CoV-2 infection and *de novo* production of infectious virus particles. Interestingly, viral infection elicited a robust intrinsic immune response where interferon (IFN) mediated responses were efficient at controlling SARS-CoV-2 replication and *de novo* infectious virus production. Importantly, human primary intestinal epithelial cells responded to SARS-CoV-2 infection by producing only type III IFN. Taken together, our data clearly highlight the importance of the enteric phase of SARS-CoV-2, and this should be taken into consideration when developing hygienic/containment measures and antiviral strategies and when determining patient prognosis.

Results {#sec2}
=======

Efficient Infection of hIECs by SARS-CoV-2 {#sec2.1}
------------------------------------------

As there is growing evidence that the gastrointestinal tract is infected by SARS-CoV-2, we engaged in studying virus infection in human intestinal epithelial cells (IECs). First, SARS-CoV-2 (strain BavPat1) was propagated in the green monkey cell line Vero. To detect viral infection, we used an antibody directed against a region of the nucleoprotein (N) that is conserved between of SARS-CoV-1 and SARS-CoV-2. Additionally, we used the J2 antibody, which detects double-stranded RNA (dsRNA), which is a hallmark of RNA virus replication ([@bib25]). Cells positive for N were always positive for dsRNA; the N signal was found to be dispersed within the cytosolic area, whereas dsRNA was found in discrete foci likely corresponding to replication compartments ([@bib6]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Supernatants of infected Vero cells were collected at 48 h post-infection (hpi), and the amount of infectious virus particles present was measured using a TCID50 approach on Vero cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The colon-carcinoma-derived lines T84 and Caco-2 cells were then infected with SARS-CoV-2 at a MOI of 0.5 (as determined in Vero cells). These cells expressed both ACE2 and TMPRSS2 ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). At different times post-infection, T84 and Caco-2 cells were fixed and immunostained using the anti-N and anti-dsRNA antibodies ([Figure 1](#fig1){ref-type="fig"}A). Results show that SARS-CoV-2-infected Caco-2 cells were readily detected as early as 4 hpi and, by 24 hpi, most of the cells were infected ([Figure 1](#fig1){ref-type="fig"}B). Similar results were observed in the T84 cells, but detection of infection was slightly delayed compared to Caco-2 cells, and, although the same amount of SARS-CoV-2 was used to infect these cells, only ∼20% of cells were infected at 24 hpi ([Figure 1](#fig1){ref-type="fig"}B). These observations are in agreement with the increase in viral genome copy numbers over time ([Figure 1](#fig1){ref-type="fig"}C) and the release of infectious virus particles in the supernatant of infected T84 and Caco-2 cells ([Figure 1](#fig1){ref-type="fig"}D). Interestingly, infection of hIECs by SARS-CoV-2 was associated with the generation of an IFN-mediated intrinsic immune response. Concomitant with the differences observed in virus replication and *de novo* virus production observed between T84 and Caco-2 cells, T84 cells mounted a much stronger immune response than Caco-2 cells ([Figures 1](#fig1){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}A), although much fewer T84 cells were infected ([Figure 1](#fig1){ref-type="fig"}B). Of note, the protein level of secreted type I IFN was under the detection limit (data not shown). Altogether, these results show that IECs are readily infected by SARS-CoV-2 and that infection of Caco-2 cells lead to a weaker intrinsic immune response that is associated with more *de novo* infectious virus production compared to T84 cells. This observation suggests that the IFN-mediated immune response controls SARS-CoV-2 infection in IECs.Figure 1Human IECs Support SARS-CoV-2 Infection, Replication, and *De Novo* Infectious Virus ProductionT84 and Caco-2 cells were infected with SARS-CoV-2 at a MOI of 0.5.(A) At indicated time points, cells were fixed and indirect immunofluorescence was performed against the viral N protein (red) and dsRNA (green). Nuclei were stained with DAPI (blue). Representative images are shown. Scale bars, 10 μm.(B) Same as (A), except the number of SARS-CoV-2-positive cells was quantified in 10 fields of view for each time point.(C) At indicated time points, RNA was harvested, and q-RT-PCR was used to evaluate the copy number of the SARS-CoV-2 genome.(D) At indicated time points, supernatants were collected from infected T84 and Caco-2 cells. The amount of *de novo* virus present in the supernatants was determined using a TCID50 assay.(E) Same as (C), except the upregulation of IFN-β1 and IFN-λ was evaluated.Error bars indicate standard deviation. n = 3 biological replicates.

IFN Hinders SARS-CoV-2 Infection in hIECs {#sec2.2}
-----------------------------------------

To directly test the function of IFNs in controlling/restricting SARS-CoV-2 replication and *de novo* infectious virus production in hIECs, T84 and Caco-2 cells were mock-treated or pretreated with type I (IFN-β1) or type III (IFN-λ) IFNs. 24 h post-treatment, cells were infected with SARS-CoV-2 at a MOI of 0.5 (as determined in Vero cells), in the presence or absence of IFNs ([Figure 2](#fig2){ref-type="fig"}A). 24 hpi, cells were immunostained using both the anti-N and anti-dsRNA antibodies. Results show that pretreatment of cells with either IFN significantly interfered with SARS-CoV-2 infection of both T84 and Caco-2 cells ([Figure 2](#fig2){ref-type="fig"}B). This decrease of the number of SARS-CoV-2-infected cells pretreated with either IFN was associated with an inhibition of the increase in viral genome copy numbers ([Figure 2](#fig2){ref-type="fig"}C) and a significant decrease in the release of infectious *de novo* virus particles ([Figure 2](#fig2){ref-type="fig"}D). These results show that both IFN-β1 and IFN-λ provided in *trans* can induce an efficient antiviral state in IECs preventing/controlling SARS-CoV-2 infection. This strongly suggests that the IFN-mediated immune response can control SARS-CoV-2 infection in human IECs.Figure 2IFN-β and IFN-λ Control SARS-CoV-2 Infection of hIECs(A) Schematic describing the experimental setup.(B) T84 and Caco-2 cells were pretreated with IFNs 24 h prior to infection. 24 hpi, virus infection was evaluated by indirect immunofluorescence for the viral N protein (red) and dsRNA (green). Nuclei were stained with DAPI (blue). Representative images are shown. The number of SARS-CoV-2-positive cells was quantified in 10 fields of view for each time point. Scale bars, 10 μm.(C) Same as (B), except RNA was harvested and qRT-PCR was used to evaluate the copy number of SARS-CoV-2 genome.(D) 24 hpi, supernatants were collected from infected T84 and Caco-2 cells. The amount of *de novo* virus present in the supernatants was determined using a TCID50 assay.n = 3 biological replicates. Error bars indicate standard deviation.

IFN-Mediated Intrinsic Immune Response Controls SARS-CoV-2 Infection in HIECs {#sec2.3}
-----------------------------------------------------------------------------

To address whether the endogenous levels of IFNs generated by IECs controls SARS-CoV-2 replication and *de novo* infectious virus production, we exploited our previously reported IECs depleted of either the type I IFN receptor (IFNAR1; AR^−/−^) or the type III IFN receptor (IFNLR1; LR^−/−^) or depleted of both IFN receptors (double knockout \[dKO\]). To control that our cells were functionally knocked out for the type I IFN (AR^−/−^) and/or the type III IFN receptor (LR^−/−^), T84 cells were treated with either IFN, and the production of the IFN-stimulated gene (ISG) IFIT1 was evaluated. As expected, type I IFN receptor knockout cells (AR^−/−^) only responded to IFN-λ, whereas type III IFN receptor knockout cells (LR^−/−^) only responded to IFN-β1 ([Figure S3](#mmc1){ref-type="supplementary-material"}A). IFN receptor dKO cells did not respond to either IFN ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Wild-type (WT) or IFN receptor knockout T84 cells were infected with SARS-CoV-2 at a MOI of 0.1 (as determined in T84 cells). 24 hpi, cells were immunostained using the anti-N antibody, and the number of infected cells was quantified using fluorescent microscopy ([Figure 3](#fig3){ref-type="fig"}A). Results showed that depletion of the type I IFN receptor (AR^−/−^) resulted in a slight increase in the number of infected cells. Importantly, depletion of the type III IFN receptor (LR^−/−^) resulted in a significant increase of cell infectivity by a factor of approximately seven. Similar results were obtained when both the type I and type III IFN receptors were depleted (dKO) ([Figure 3](#fig3){ref-type="fig"}B). Interestingly, this increase in the number of infected cells upon depletion of the type III IFN receptor (LR^−/−^) was associated with a significant increase in viral genome copy numbers ([Figure 3](#fig3){ref-type="fig"}C) and with a three-orders-of-magnitude increase in *de novo* infectious virus production ([Figure 3](#fig3){ref-type="fig"}D). Together, these results suggest that the type-III-IFN-mediated immune response actively participates in controlling SARS-CoV-2 infection in human IECs.Figure 3Type III IFN Receptor Controls SARS-CoV-2 Replication in hIECs(A--D) WT T84 cells and T84 cells depleted of the type I IFN receptor (AR^−/−^), the type III IFN receptor (LR^−/−^), or both (dKO) were infected with SARS-CoV-2 at an MOI of 0.1. (A) 24 hpi, infection was analyzed by indirect immunofluorescence of the viral N protein (red). Nuclei were stained with DAPI (blue). Representative images are shown. Scale bars, 10 μm. (B) Same as (A), except the number of SARS-CoV-2-positive cells was quantified in 10 fields of view for each cell type. (C) 24 hpi, RNA was harvested and the change in the copy number of SARS-CoV-2 genome was evaluated by qRT-PCR. (D) 24 hpi, supernatants were collected from all cell types. The amount of *de novo* virus present in the supernatants was determined using a TCID50 assay.(E--G) WT T84 cells were mock-treated or pretreated with pyridine-6, a pan-JAK inhibitor, for 2 h prior to SARS-CoV-2 infection. (E) 24 hpi, infection was analyzed by indirect immunofluorescence of the viral N protein (red). Nuclei were stained with DAPI (blue). Representative images are shown. Scale bars, 10 μm. (F) 24 hpi, RNA was harvested and the change in the copy number of SARS-CoV-2 genome was evaluated by qRT-PCR. (G) 24 hpi, supernatants were collected from mock-treated or pan-JAK-treated cells. The amount of *de novo* virus present in the supernatants was determined using a TCID50 assay.n = 3 biological replicates. Error bars indicate standard deviation.

To unambiguously address the importance of the IFN-mediated antiviral response, we used the pan-JAK inhibitor (pyridone-6) to inhibit the STAT1 phosphorylation activation and block the production of ISGs. As we previously reported, treatment of T84 cells with the pan-JAK inhibitor fully inhibits signal transduction downstream both the type I and type III IFN receptors ([@bib18]; and data not shown). Mock-treated and pyridone-6 pretreated T84 cells were infected with SARS-CoV-2 for 24 h and analyzed using fluorescence microscopy following immunostaining using the anti-N antibody. Results show both a significant increase in the number of infected cells ([Figure 3](#fig3){ref-type="fig"}E) and an increase of viral genome copy number in cells treated with the pan-JAK inhibitor ([Figure 3](#fig3){ref-type="fig"}F). Importantly, and in agreement with the results observed in cells depleted of the type III IFN receptor, this increase in infectivity was also associated with an increase in infectious *de novo* virus particle production ([Figure 3](#fig3){ref-type="fig"}G). Altogether, these results strongly support a model where type-III-IFN-mediated signaling controls SARS-CoV-2 infection in hIECs.

Human Primary Intestinal Organoids Support SARS-CoV-2 Infection, Replication, and *De Novo* Infectious Virus Production {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------

To address whether primary hIECs can be infected by SARS-CoV-2 and support *de novo* virus production, we used human-colon-derived organoids from two distinct donors. Intact ultrastructural organization and differentiation to all cell types (e.g., enterocytes, Goblet cells, enteroendocrine cells, and stem cells) was confirmed using confocal fluorescent microscopy ([Figure 4](#fig4){ref-type="fig"}A) and qRT-PCR against cell-type-specific transcripts ([Figure 4](#fig4){ref-type="fig"}B). As quantification of the number of infected cells in 3D organoids is very challenging, we exploited previously established protocols to differentiate and infect human intestinal organoids in two dimensions with viruses ([@bib5]; [@bib24]). Nondifferentiated organoids were seeded on human-collagen-coated iBIDI chambers. At 24 h post-seeding, differentiation was induced by removal of Wnt3a and reducing the amounts of R-spondin and Noggin for 4 days. Upon full differentiation, organoids were infected with SARS-CoV-2. At 24 hpi, infection was analyzed by immunostaining using the anti-N and anti-dsRNA antibodies and by qRT-PCR ([Figure 4](#fig4){ref-type="fig"}C). Results show that independent of the donor, colon organoids were readily infected by SARS-CoV-2, as noted by the presence of cells positive for both N and dsRNA ([Figure 4](#fig4){ref-type="fig"}D). Quantification revealed that ∼8%--13% of cells were infected in each donor ([Figure 4](#fig4){ref-type="fig"}E). This infection was associated with an increase of viral genome copy number ([Figure 4](#fig4){ref-type="fig"}F). Interestingly, infection of organoids led to no type I IFN (IFN-β1) production but an extremely large upregulation of type III IFN (IFN-λ) ([Figures 4](#fig4){ref-type="fig"}G, [S2](#mmc1){ref-type="supplementary-material"}B, and [S3](#mmc1){ref-type="supplementary-material"}B). To determine if exogenously added IFNs could prevent SARS-CoV-2 infection, colon organoids were mock-treated or pretreated with IFN-β1 and IFN-λ and then subsequently infected with SARS-CoV-2 for 24 h. Results show that pretreatment of colon organoids with both IFN-β1 and IFN-λ significantly impaired infection ([Figure 4](#fig4){ref-type="fig"}H). This was associated with a reduction of SARS-CoV-2 genome copy numbers ([Figure 4](#fig4){ref-type="fig"}I) and a decrease in infectious *de novo* virus particle production ([Figure 4](#fig4){ref-type="fig"}J). Altogether, these results show that human colon organoids can support SARS-CoV-2 infection, replication, and *de novo* infectious virus production and that the type III IFN response plays a critical role in controlling virus replication.Figure 4Human Colon Organoids Support SARS-CoV-2 Infection, Replication, and *De Novo* Infectious Virus Production(A) Bright-field and immunofluorescence images showing human colon organoids that express markers for enterocytes (E-cadherin \[E-Cad\]), goblet cells (mucin \[MUC-2\]), and enteroendocrine cells (synaptophysin \[SYP\]). Representative images are shown. Scale bars, 25 μm.(B) Colon organoids were differentiated prior to infection with SARS-CoV-2. Differentiation was confirmed by qRT-PCR for stem cell markers (OLFM4), enterocytes (sucrase isomaltase \[SI\]), and goblet cells (MUC-2).(C) Schematic describing method for infection of 2D colon organoids with SARS-CoV-2.(D--G) Colon organoids were seeded in 2D and differentiated prior SARS-CoV-2 infection. 24 hpi, cells were analyzed for virus replication and immune response. (D) Infection was analyzed by indirect immunofluorescence of the viral N protein (red) and dsRNA (green). Nuclei were stained with DAPI (blue). Representative images are shown. Scale bars, 10 μm. (E) The number of SARS-CoV-2-positive cells were quantified in 10 fields for each donor. (F) RNA was harvested, and the change in the copy number of SARS-CoV-2 genome was evaluated by qRT-PCR. (G) Same as F, except the upregulation of IFN-β1 and IFN-λ was evaluated.(H--J) Colon organoids were pretreated with IFNs 24 h prior to infection. (H) 24 hpi, virus infection was evaluated by indirect immunofluorescence for the viral N protein (red) and dsRNA (green). Nuclei were stained with DAPI (blue). Representative images are shown. The number of SARS-CoV-2-positive cells was quantified in 10 fields of view for each time point. Scale bars, 10 μm. (I) RNA was harvested, and qRT-PCR was used to evaluate the copy number of SARS-CoV-2 genome. (J) Supernatants were collected from infected organoids. The amount of *de novo* viruses present in the supernatants was determined using a TCID50 assay.n = 3 biological replicates. Error bars indicate standard deviation.

Discussion {#sec3}
==========

Increasing numbers of clinical reports detail that COVID-19 patients not only have severe respiratory symptoms but also show indications of gastrointestinal pathologies. To efficiently combat the pandemic, it is necessary to fully appreciate the complexity of the disease, and this requires that the virus life cycle and its interaction with the host are characterized for each site of infection (e.g., lung versus gut). Here, we report that hIECs, including primary non-transformed epithelial cells, fully support SARS-CoV-2 infection, replication, and *de novo* infectious virus production. Interestingly, infection of primary hIECs by SARS-CoV-2 induces a robust intrinsic immune response characterized by the production of type III IFNs, but not type I IFN. Pretreatment of hIECs with exogenous IFNs prior to SARS-CoV-2 infection results in a major drop of the number of infected cells, a reduction of viral replication, and a significant decrease in the production of infectious *de novo* virus particles. Concomitantly, inhibition of type III IFN signaling by genetic ablation of its specific receptor results in a significant increase of SARS-CoV-2 replication and secretion. Together, our results demonstrate that hIECs are a productive site of SARS-CoV-2 replication, and this may have critical implications for the etiology of both SARS-CoV-2 infection and the pathologies observed in COVID-19 patients. Additionally, our work highlights the central role of type III IFN in controlling SARS-CoV-2 at the intestinal epithelium.

Primary hIECs cells support robust replication of SARS-CoV-2 and secretion of infectious *de novo* virus particles. We found that ∼10% of the cells are infected in a human-colon-derived organoid, leading to a modest but significant increase in viral genome copy number ([Figure 4](#fig4){ref-type="fig"}F) and *de novo* infectious virus particles ([Figure 4](#fig4){ref-type="fig"}J) over time. This modest replication of SARS-CoV-2 is explained by the fact that (1) only a small fraction of the cells are infected by SARS-CoV-2, and (2) as shown in this work, IFNs are potent inhibitors of SARS-CoV-2 replication ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), and organoids are highly immunoresponsive upon viral infection ([@bib24]) ([Figure 4](#fig4){ref-type="fig"}G). Our findings are in agreement with recent work from Lamers et al. showing that infection of human intestinal organoids by SARS-CoV-2 induces a strong immune response characterized by a strong expression of ISGs ([@bib9]). Interestingly, in this work, expression of type III IFN was shown to be very low. This is contrary to our data showing high production of type III IFN; however, we monitored IFN-λ2/3 levels, while the other study monitored IFN-λ1 levels. Further work is necessary to address if different subtypes of type III IFNs are induced by SARS-CoV-2. It is well known that *in vivo* intestinal epithelium cells are less immunoresponsive because of the gut microenvironment (e.g., microbiota and tissue-specific immune cells) and as such they will very likely show a severely dampened immune response allowing for an even greater SARS-CoV-2 replication.

Analysis of the single-cell RNA sequencing data from the Colon Atlas revealed that only 3.8% of human colon epithelial cells express very low levels of the SARS-CoV-2 receptor ACE-2 ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4E). This is very different to the small intestine where ACE-2 appears to be more expressed ([@bib21]). This low ACE-2 level could explain why we have a small percentage of infected cells in our colon organoids ([Figure 4](#fig4){ref-type="fig"}E). On the contrary, TMPRSS2 seems to be not a limiting factor in the colon ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4E). Interestingly, q-RT-PCR and western blot analysis do not support single-cell analysis and clearly show that ACE-2 is expressed in both our carcinoma derived lines and our colon organoids ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). The discrepancy between the single-cell RNA sequencing and classical molecular and biochemical approaches is likely the results of (1) the sequencing being not deep enough to detect ACE-2 in individual cells and (2) RNA expression not necessarily matching the protein expression levels. These observations highlight that although analyzing data from single-cell RNA sequencing atlases could be very informative, their findings should be validated in tissues, as they may be misleading or miss important sites of virus replication.

Human colon carcinoma Caco-2 cells produce very large amounts of infectious viral particles. This is higher than the titers obtained in Vero cells, which are commonly used to isolate and propagate SARS-CoV-2 ([@bib7]) ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Similarly, the lung cell line Calu-3 produced much fewer infectious virus particles than Caco-2 cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Interestingly, in a study comparing 13 different human cell lines, Caco-2 cells were the only cell type found to support SARS-CoV-1 replication, and, compared to green monkey cells, Caco-2 cells were very efficient in producing infectious *de novo* virus particles and did not show cytopathic effects ([@bib16]). These observations that Caco-2 are excellent culture models supporting both SARS-CoV-2 and SARS-CoV-1 further highlight the potentially central role of intestinal epithelial cells in COVID-19 patients. Intriguingly, T84 cells, which are also colon-carcinoma-derived cells, supported SARS-CoV-2 infection, replication, and *de novo* infectious virus production but to a much lesser extent compared to Caco-2 cells. Analysis of the intrinsic immune response generated upon infection of both cell lines revealed that T84 cells are more immunoresponsive than Caco-2 cells. In light of the results obtained by pretreating cells with exogenous IFNs, we propose that T84 cells, by being able to mount a stronger and faster immune response than Caco-2 cells, can better restrict SARS-CoV-2 infection. This model is fully supported by our IFN receptor knockout T84 cells, in which virus replication and *de novo* virus production are drastically increased to levels similar to the ones observed in Caco-2 cells.

Exogenously added type I and III IFNs induce an antiviral state in our hIECs, thereby restricting SARS-CoV-2 replication in these cells. Similar observations were made with type I IFN in Vero cells ([@bib14]). Interestingly, infection of Calu-3 human lung epithelial cells by SARS-CoV-2 also seems to mount an immune response ([@bib11]), whereas in A549 cells, in ferret models and human lung tissues, SARS-CoV-2 infection leads to the induction of a restricted and muted immune response lacking the induction of type I and type III IFNs ([@bib1]; [@bib2]). The reason for the difference in the amount of IFN made upon infection of lung versus intestinal epithelial cells is currently unclear. Like intestinal epithelial cells ([@bib18], [@bib19]; [@bib20]), lung epithelial cells are normally highly immunoresponsive and make IFNs upon viral infection ([@bib3]; [@bib38]). The lack of IFN in lung epithelial cells following SARS-CoV-2 infection might be specific for this virus in this tissue ([@bib1]), as SARS-CoV-1 induces IFN production in infected lung tissue ([@bib2]). Importantly, our work shows that compared to the airway epithelium, the intestinal epithelium produces a typical antiviral response. This highlights that host-pathogen interaction should be considered in a tissue-specific manner, as different cellular responses and viral countermeasures might be established among the lung, gut, and other organs.

Interestingly, in human colon organoids, we observed that only type III IFN is made upon SARS-CoV-2 infection, although human intestinal organoids are capable of making both type I and III IFN upon enteric virus infection ([@bib19]; [@bib24]). The lack of type I induction could be due to a kinetic delay of type I IFN production compared to type III IFN but this will need to be carefully addressed in further experiments. Another possibility is that SARS-CoV-2 encodes a specific antagonist that counteracts the production of type I IFN only. However, further studies are necessary to prove this novel concept. Additionally, the observation that the knockout of the type III IFN receptor leads to a much greater increase of SARS-Cov-2 infection, replication, and *de novo* virus production compared to knockout of the type I receptor ([Figures 3](#fig3){ref-type="fig"}A--3D) further highlights the central role of type III IFN in SARS-CoV-2 infection of human intestinal epithelium cells.

We propose that the gut is an active site of replication for SARS-CoV-2, and this could account for the viremia observed in COVID-19 patients and the presence of large amounts of SARS-CoV-2 genomes in the feces. The origin of the replicating SARS-CoV-2 in the intestinal epithelium is still not clear. To date, only one paper reported the isolation of infectious virus from stool samples ([@bib29]). Further characterization of the SARS-CoV-2 enteric life cycle is necessary to determine whether the viral infection observed in the gut is due to fecal/oral transmission or is a manifestation of virus spreading from the lung to the gut. In the context of the gut we foresee that at the onset of SARS-CoV-2 infection, hIECs will mount an antiviral response through the type III IFN signaling pathway. As immune cells participate in mounting an innate immune response, type I IFN will be secreted from these cells and will be able to act on intestinal epithelial cells further reinforcing their antiviral state against SARS-CoV-2. In respect to the severe pathologies observed in the lung, which are believed to be caused by a cytokine storm, the findings that lung epithelial cells mount a muted immune response upon SARS-CoV-2 infection suggests that the cytokines are coming from an alternative source. This source could be from local immune cells or the gastrointestinal mucosa given the large immune response generated by primary hIECs. As a matter of fact, many cytokines are released from epithelial cells toward the lamina propria (tissue side) ([@bib23]) and will quickly enter the circulation to potentially fuel and promote the inflammation and pathology observed in the lung.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti-SARS CoV NPSino BiologicalsCat\#MM05Mouse monoclonal anti-dsRNA (J2)ScionsCat\#10010200; RRID:[AB_2651015](nif-antibody:AB_2651015){#interref50}Mouse monoclonal anti-E-cadherinBD TransductionsCat\#610181Rabbit polyclonal anti-ACE2AbcamCat\#ab15348Rabbit polyclonal anti-Mucin-2Santa Cruz BiotechCat\# sc-15334; RRID:[AB_2146667](nif-antibody:AB_2146667){#interref55}Mouse monoclonal anti-SYPSanta Cruz BiotechCat\#sc-17750; RRID:[AB_628311](nif-antibody:AB_628311){#interref60}Mouse polyclonal anti-beta actinSigma AldrichCat\#A5441Alexa Fluor Goat anti mouse 488Thermo Fischer ScientificCat\#A-11001; RRID:[AB_2534069](nif-antibody:AB_2534069){#interref65}Alexa Fluor Goat anti rabbit 488Thermo Fischer ScientificCat\#A-11034; RRID:[AB_2576217](nif-antibody:AB_2576217){#interref70}Alexa Fluor Goat anti mouse 568Thermo Fischer ScientificCat\#A-21124; RRID:[AB_2535766](nif-antibody:AB_2535766){#interref75}Alexa Fluor Goat anti rabbit 568Thermo Fischer ScientificCat\#A-11011; RRID:[AB_143157](nif-antibody:AB_143157){#interref80}Anti-Mouse IgG IRDye CW800Li-CorCat\#926-32212; RRID:[AB_621847](nif-antibody:AB_621847){#interref85}Anti-rabbit IgG IRDye CW800Li-CorCat\#926-32213; RRID:[AB_621848](nif-antibody:AB_621848){#interref90}Anti-mouse IgG IRDye CW680Li-CorCat\#926-68072; RRID:[AB_10953628](nif-antibody:AB_10953628){#interref95}**Bacterial and Virus Strains**BavPat1/2020European Virology Archives026V-03883**Biological Samples**Human colon resectionsUniversity Hospital HeidelbergN/A**Chemicals, Peptides, and Recombinant Proteins**Advanced DMEM/F12Thermo Fischer ScientificCat\# 12634010HEPESThermo Fischer ScientificCat3 15630080Penicillin/StreptomycinThermo Fischer ScientificCat\#15140122GlutaMAXThermo Fischer ScientificCat\# 35050061EDTASigma AldrichCar\#E9884MatriGel. GFR, LDEV freeCorningCat\#354230B27Thermo Fischer ScientificCat\#17504-044N-acetyl-cysteineSigma AldrichCat\# A9165Recombinant mouse EGFThermo Fischer ScientificCat\# PMG8043\[Leu15\]-Gastrin ISigma-AldrichCat\# G9145A83-01TocrisCat\#2939Recombinant human IGF-1BioLegendCat\#590904Recombinant human FGF basicPeprotechCat\#100-18BY-27632Caymann ChemicalsCat\#10005583Mouse recombinant nogginPeprotechCat\#250-38Human recombinant IFN-beta 1BiomolCat\#86421Recombinant human IFNL1PeprotechCat\#300-02LRecombinant human IFNL2PeprotechCat\#300-02KRecombinant human IFNL3BiomolCat\#179-ML-025Pyridone 6CalbiochemCat\#420099-500Collagen from human placentaSigma AldrichCat\#C5533-5MG0.05% Trypsin-EDTAThermo Fischer ScientificCat\#25300054iTaq Universal SYBR green SupermixBioRadCat\#1725120ParafolmaldehydeSigma AldrichCat\#158127Triton X-100Sigma AldrichCat\#X100DAPISigma AldrichCat\#D9542Fetal Bovine SerumCapricornCat\#FBS-11ADMEM, high glucoseThermo Fischer ScientificCat\#11965092DMEM/F12Thermo Fischer ScientificCat\#11320033Draq5AbcamCat\#ab108410Beta propiolactoneSigma AldrichCat\#457604**Critical Commercial Assays**RNAeasy RNA extraction kitQIAGENCat\#74104iSCRIPT cDNA synthesis kitBioRadCat\#1708890DIY IFNL2/3 ELISAPBL Interferon sourceCat\#61830-1**Deposited Data**Single-cell RNA sequencing data of human colon samples.[@bib22]Single Cell Portal, accession number SCP259 (<https://singlecell.broadinstitute.org/single_cell/study/SCP259/intra-and-inter-cellular-rewiring-of-the-human-colon-during-ulcerative-colitis>)**Experimental Models: Cell Lines**T84 human colon carcinoma cellsATCCCCL-248T84 IFNLR−/−[@bib19]N/AT84 IFNAR−/−[@bib19]N/AT84 IFNLR/IFNAR−/− dKO[@bib19]N/ACaco-2 human colorectal adenocarcinomaATCCHTB-37Vero E6ATCCCRL 1586Human colon organoidsThis paperN/AL-WRNATCCCRL-3276**Oligonucleotides**TBP for ccactcacagactctcacaacEurofinsN/ATBP rev ccactcacagactctcacaacEurofinsN/AHPRT1 for cctggcgtcgtgattagtgatEurofinsN/AHPRT1 rev agacgttcagtcctgtccataaEurofinsN/AIFNL2/3 for gccacatagcccagttcaagEurofinsN/AIFNL2/3 rev tgggagaggatatggtgcagEurofinsN/AIFNb1 for gccgcattgaccatctatEurofinsN/AIFNb1 rev gtctcattccagccagtgEurofinsN/AOLFM4 for acctttcccgtggacagagtEurofinsN/AOLFM4 rev tggacatattccctcactttggaEurofinsN/ASI for aatccttttggcatccagattEurofinsN/ASI rev gcagccaagaatcccaaatEurofinsN/AMUC-2 for tgtaggcatcgctcttctcaEurofinsN/AMUC-2 rev gacaccatctacctcacccgEurofinsN/AACE-2 for tcaaggaggccgagaagttcEurofinsN/AACE-2 rev ttcctgggtccgttagcatgEurofinsN/ATMPRSS2 for acctgatcacaccagccatg/EurofinsN/ATMPRSS2 rev cttcgaagtgaccagaggccEurofinsN/ACOV1 for gcctcttctgttcctcatcacEurofinsN/ACOV1 rev agacagcatcaccgccattgEurofinsN/A**Software and Algorithms**R (version 3.6.1)Comprehensive R Archive Network (CRAN)<https://cran.r-project.org/>Seurat R package (version 3.1.4)R package<https://satijalab.org/seurat/get_started.html> (RRID:[SCR_016341](rridsoftware:SCR_016341){#intref0025})

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Megan L. Stanifer (<m.stanifer@dkfz.de>)

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

This study did not generate any unique datasets or code. No custom code was used to analyze these data and all methods and packages used are cited in the methods section.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cells {#sec4.3.1}

T84 human colon carcinoma cells (ATCC CCL-248) and their knock-out clones were maintained in a 50:50 mixture of Dulbecco's modified Eagle's medium (DMEM) and F12 (GibCo) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (GIBCO). Caco-2 human colorectal adenocarcinoma (ATCC HTB-37) and Vero E6 (ATCC CRL 1586) were maintained in Dulbecco's modified Eagle's medium (DMEM) (GibCo) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (GIBCO).

### Viruses {#sec4.3.2}

SARS-CoV-2 (strain BavPat1) was obtained from Prof. Christian Drosten at the Charité in Berlin, Germany and provided via the European Virology Archive. The virus was amplified in Vero E6 cells.

### Human organoid cultures {#sec4.3.3}

Human tissue was received from colon resection from the University Hospital Heidelberg. This study was carried out in accordance with the recommendations of the University Hospital Heidelberg with informed written consent from all subjects in accordance with the Declaration of Helsinki. All samples were received and maintained in an anonymized manner. The protocol was approved by the "Ethics commission of the University Hospital Heidelberg" under the protocol S-443/2017. Stem cells containing crypts were isolated following 2 mM EDTA dissociation of tissue sample for 1 h at 4°C. Crypts were spun and washed in ice cold PBS. Fractions enriched in crypts were filtered with 70 μM filters and the fractions were observed under a light microscope. Fractions containing the highest number of crypts were pooled and spun again. The supernatant was removed, and crypts were re-suspended in Matrigel. Crypts were passaged and maintained in basal and differentiation culture media (see [Table S1](#mmc1){ref-type="supplementary-material"}).

Method Details {#sec4.4}
--------------

### Antibodies and Inhibitors {#sec4.4.1}

Mouse monoclonal antibody against SARS-CoV NP (Sino biologicals MM05), mouse monoclonal against J2 (scions), mouse monoclonal against E-cadherin (BD Transductions \#610181), mouse monoclonal anti-SYP (Santa Cruz Biotechnology sc-17750), and rabbit polyclonal anti-Mucin-2 (Santa Cruz Biotechnology\# sc-15334) were used at 1:500 for immunofluorescence. Rabbit polyclonal ACE-2 antibody (Abcam) was used at 1:500 and mouse polyclonal actin was used at 1:5000 for western blot. Secondary antibodies were conjugated with AF488 (Molecular Probes), AF568 (Molecular Probes), CW680 (Li-Cor) or CW800 (Li-Cor) directed against the animal source. Human recombinant IFN-beta1a (IFNβ) was obtained from Biomol (\#86421) was used at a final concentration of 2,000IU/mL. Recombinant human IFNλ 1 (IL-29) (\#300-02L), IFNλ 2 (IL28A) (\#300-2K)) were purchased from Peprotech and and IFNλ 3 (IL-28B) was purchased from BioMol. All three lambda interferons were combined and were used at a concentration of 100ng/mL each to make a final concentration of 300ng/mL, Pyridone 6 (Calbiochem \#420099-500)was used at a final concentration of 2uM.

### Viral infections {#sec4.4.2}

All SARS-CoV-2 infections were performed the MOI indicated in the text. Media was removed from cells and virus was added to cells for 1 hour at 37°C. Virus was removed, cells were wash 1x with PBS and media or media containing inhibitors/cytokines was added back to the cells.

### 2D organoid seeding {#sec4.4.3}

8-well iBIDI glass bottom chambers were coated with 2.5% human collagen in water for 1 h prior to organoids seeding. Organoids were collected at a ratio of 100 organoids/transwell. Collected organoids were spun at 450 g for 5 mins and the supernatant was removed. Organoids were washed 1X with cold PBS and spun at 450 g for 5 mins. PBS was removed and organoids were digested with 0.05% Trypsin-EDTA (Life technologies) for 5 mins at 37°C. Digestion was stopped by addition of serum containing medium. Organoids were spun at 450 g for 5 mins and the supernatant was removed and organoids were re-suspended in normal growth media at a ratio of 250 μL media/well. The collagen mixture was removed from the iBIDI chambers and 250 μL of organoids were added to each well.

### RNA isolation, cDNA, and qPCR {#sec4.4.4}

RNA was harvested from cells using RNAeasy RNA extraction kit (QIAGEN) as per manufactures instructions. cDNA was made using iSCRIPT reverse transcriptase (BioRad) from 250 ng of total RNA as per manufactures instructions. q-RT-PCR was performed using iTaq SYBR green (BioRad) as per manufacturer's instructions, TBP or HPRT1 were used as normalizing genes. Primer used:

### Indirect Immunofluorescence Assay {#sec4.4.5}

Cells seeded on iBIDI glass bottom 8-well chamber slides. At indicated times post-infection, cells were fixed in 4% paraformaldehyde (PFA) for 20 mins at room temperature (RT). Cells were washed and permeabilized in 0.5% Triton-X for 15 mins at RT. Primary antibodies were diluted in phosphate-buffered saline (PBS) and incubated for 1h at RT. Cells were washed in 1X PBS three times and incubated with secondary antibodies and DAPI for 45 mins at RT. Cells were washed in 1X PBS three times and maintained in PBS. Cells were imaged by epifluorescence on a Nikon Eclipse Ti-S (Nikon).

### In-cell Western {#sec4.4.6}

20,000 Vero E6 cells were seeded per well into a 96-well dish 24h prior to infection. 100uL of harvested supernatant was added to the first well. Seven 1:10 dilutions were made (all samples were performed in triplicate). Infections were allowed to proceed for 24h. 24h post-infection cells were fixed in 2% PFA for 20mins at RT. PFA was removed and cells were washed twice in 1X PBS and then permeabilized for 10mins at RT in 0.5% Triton-X. Cells were blocked in a 1:2 dilution of Li-Cor blocking buffer (Li-Cor) for 30mins at RT. Cells were stained with 1/1000 dilution anti-dsRNA (J2) for 1h at RT. Cells were washed three times with 0.1% Tween in PBS. Secondary antibody (anti-mouse CW800) and DNA dye Draq5 (Abcam) were diluted 1/10,000 in blocking buffer and incubated for 1h at RT. Cells were washed three times with 0.1% Tween/PBS. Cells were imaged in 1X PBS on a LICOR (Li-Cor) imager.

### Western blot {#sec4.4.7}

At time of harvest, media was removed, cells were rinsed once with 1X PBS and lysed with 1X RIPA (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris, pH 8.0 with phosphatase and protease inhibitors (Sigma-Aldrich)) for 5 mins at room temperature (RT). Lysates were collected and equal protein amounts were separated by SDS-PAGE and blotted onto a nitrocellulose membrane by wet-blotting (Bio-Rad). Membranes were blocked with Li-Cor blocking buffer (Li-Cor) for one hour at RT. Primary antibodies were diluted in blocking buffer and incubated overnight at 4°C. Membranes were washed 3X in TBS-T for 5 mins at RT. Secondary antibodies were diluted in blocking buffer and incubated at RT for 1 hour with rocking. Membranes were washed 3X in TBS-T for 5 mins at RT and scanned on a Li-Cor scanner.

### ELISA {#sec4.4.8}

Supernatants were collected at indicated time points. Virus in supernatants was inactivated with 0,05% beta propiolactone (BPL) (Sigma-Aldrich) overnight at 4°C. BPL was hydrolyzed at 37°C for 2 hours prior to ELISA. ELISA standards were also diluted in 0.05% BPL overnight following 2h hydrolyzation at 37°C. IFNλ2/3 was evaluated using the IFNλ2/3 DIY ELISA (PBL Interferon source) as per manufacturer's instructions.

### Re-processing of the single-cell RNaseq Human Colon Atlas {#sec4.4.9}

The data from the single-cell transcriptome human colon atlas ([@bib22]) was obtained from the broad institute Single Cell Portal accession number SCP259 (<https://singlecell.broadinstitute.org/single_cell/study/SCP259/intra-and-inter-cellular-rewiring-of-the-human-colon-during-ulcerative-colitis>). Expression matrices of the epithelial subset of 30 samples were imported and individually analyzed using the Seurat software, version 3.1.4 (<https://github.com/satijalab/seurat>). Quality filtering was performed, and cells having fewer than 500 genes and more than 30% of UMI count mapped to mitochondrial genes were discarded. Consecutively, the resulting datasets were normalized, scaled and high-variance genes genes were selected. Reciprocal PCA-based data integration was done to merge the samples. Afterward, the resulting batch-corrected counts were used for calculating PCA-based dimensionality reduction and unsupervised Louvain clustering. Furthermore, UMAP visualization was calculated using 50 neighboring points for the local approximation of the manifold structure. Cell type annotation was based on the unsupervised clustering and the metadata provided by the colon atlas ([@bib22]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Unless otherwise stated, P values were calculated by a two-tailed unpaired t test using the GraphPad Prism software package. All samples were analyzed without blinding or exclusion of samples. N values indicate the number of biological replicates for a sample.
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